See more : Cool Chips plc (COLCF) Income Statement Analysis – Financial Results
Complete financial analysis of EGF Theramed Health Corp. (EVAHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EGF Theramed Health Corp., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Clover Health Investments, Corp. (CLOV) Income Statement Analysis – Financial Results
- Ateam Inc. (3662.T) Income Statement Analysis – Financial Results
- Personal Group Holdings Plc (PGH.L) Income Statement Analysis – Financial Results
- Spacefy Inc. (SPFY.CN) Income Statement Analysis – Financial Results
- Global Partner Acquisition Corp II (GPACU) Income Statement Analysis – Financial Results
EGF Theramed Health Corp. (EVAHF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.egftheramedhealth.com
About EGF Theramed Health Corp.
EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 105.23 | 176.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -105.23 | -176.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 232.71 | 36.22K | -217.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 433.54K | 989.06K | 1.11M | 1.83M | 1.98M | 541.94K | 1.08M | 170.38K | 385.05K | 26.97K | 339.55K | 2.98K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 237.00 | 4.66K | 24.00 | 0.00 | 51.00 |
| SG&A | 433.54K | 989.06K | 1.11M | 1.83M | 1.98M | 541.94K | 1.08M | 170.62K | 389.70K | 26.99K | 339.55K | 3.03K |
| Other Expenses | 172.57K | 0.00 | -105.23K | -577.01K | -672.60K | -346.78K | -3.25K | -6.63K | 133.49K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 606.11K | 989.06K | 1.21M | 2.62M | 1.98M | 541.94K | 1.08M | 170.62K | 389.70K | 26.99K | 339.55K | 3.03K |
| Cost & Expenses | 606.11K | 989.06K | 1.21M | 2.62M | 1.98M | 541.94K | 1.08M | 170.62K | 389.70K | 26.99K | 339.55K | 3.03K |
| Interest Income | 0.00 | 698.00 | 4.82K | 2.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 |
| Interest Expense | 38.76K | 14.53K | 65.44K | 177.38K | 7.57K | 55.58K | 253.00 | 76.05K | 6.60K | 27.14K | 0.00 | 0.00 |
| Depreciation & Amortization | 38.76K | 971.35 | 866.07 | 176.36K | -180.86K | 58.80K | -184.30K | -36.73K | -15.17K | -329.00 | 3.00 | 0.00 |
| EBITDA | -567.35K | -989.66K | -1.21M | -2.46M | -2.79M | -889.34K | -1.26M | -207.34K | -404.87K | -27.32K | -339.55K | -3.03K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -606.11K | -1.00M | -1.28M | -2.80M | -2.61M | -948.14K | -1.08M | -170.62K | -389.70K | -26.99K | -339.55K | -3.03K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -37.36K | -359.02K | 535.07K | -18.82M | -12.03M | 11.99K | -25.64M | -24.66K | 111.72K | -27.47K | 3.00 | 0.00 |
| Income Before Tax | -643.48K | -1.36M | -744.31K | -21.62M | -14.40M | -936.15K | -26.72M | -195.28K | -277.98K | -54.46K | -339.55K | -3.03K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -14.22K | 224.40K | -1.22M | -624.17K | -350.00K | 10.40M | 112.78K | 21.76K | 27.14K | 0.00 | 0.00 |
| Net Income | -623.00K | -1.35M | -973.53K | -20.23M | -14.40M | -936.15K | -36.94M | -195.28K | -277.98K | -54.46K | -339.55K | -3.03K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.63 | -0.91 | -124.25 | -375.38 | -3.85 | -403.18 | -55.02 | -4.34 | -38.90 | -276.50 | -2.06 |
| EPS Diluted | -0.06 | -0.63 | -0.91 | -124.25 | -375.38 | -3.85 | -268.15 | -55.02 | -3.50 | -38.90 | -276.50 | -0.13 |
| Weighted Avg Shares Out | 9.99M | 2.16M | 1.07M | 162.81K | 38.35K | 242.92K | 91.61K | 3.55K | 63.98K | 1.40K | 1.23K | 1.47K |
| Weighted Avg Shares Out (Dil) | 9.99M | 2.16M | 1.07M | 162.81K | 38.35K | 242.92K | 137.75K | 3.55K | 79.32K | 1.40K | 1.23K | 22.53K |
EGF Theramed Joint Venture Partner Pharmadelic Labs Announces Lab Services Agreement With Numinus Wellness
Source: https://incomestatements.info
Category: Stock Reports